Preview

Пульмонология

Расширенный поиск

Эффекты фиксированных комбинаций ингаляционных кортикостероидов и длительнодействующих β2-агонистов при хронической обструктивной болезни легких

https://doi.org/10.18093/0869-0189-2008-0-6-101-108

Полный текст:

Об авторах

З. Р. Айсанов
ФГУ НИИ пульмонологии ФМБА России
Россия
Москва


Е. Н. Калманова
ФГУ НИИ пульмонологии ФМБА России
Россия
Москва


О. Ю. Стулова
ФГУ НИИ пульмонологии ФМБА России
Россия
Москва


Список литературы

1. World Health Organization. Chronic obstructive pulmonary disease (COPD) data fact sheet no. 315. Available from; www.who.int/mediacentre/factsheets/fs315/en/index.html.

2. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709–721.

3. Hogg J.C., Chu F., Utokaparch S. et al. The nature of small airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645–2653.

4. Turato G., Zuin R., Miniati M. et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am. J. Respir. Crit. Care Med. 2002; 166: 105–110.

5. Keatings V.M., Jatakanon A., Worsdell Y.M., Barnes P.J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 1997; 155: 542–548.

6. Agusti A.G. COPD, a multicomponent disease: implications for management. Respir. Med. 2005; 99: 670–682.

7. Wouters E.F., Creutzberg E.C., Schols A.M. Systemic effects in COPD. Chest 2002; 121: 127S–130S.

8. Global Initiative for Chronic Obstructive Lung Disease. Updated December 2007. Available from; www.goldcopd.com.

9. Celli B.R., MacNee W., ATS / ERS committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.

10. Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.

11. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Longterm treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1948–1953.

12. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902–1909.

13. Sutherland E.R., Allmers H., Ayas N.T. et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a metaanalysis. Thorax 2003; 58: 937–941.

14. Soriano J.B., Sin D.D., Zhang X. et al. A poled analysis of FEV 1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682–689.

15. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456.

16. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 1084–1091.

17. Hanania N.A., Darken P., Horstman D. et al. The efficacy and safety of fluticasone propionate (250 mg) / salmeterol (250 mg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834–843.

18. Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol / fluticasone propionate versus salmeterol on exacerbations in severe COPD. Am. J. Respir. Crit. Care Med. 2007; 175: 144–149.

19. Vogelmeier C.F., Wencker M., Glaab T., Kardos P. Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol / fluticasone propionate (SFC) with salmeterol (SAL) treatment. Proc. Am. Thorac. Soc. 2006; 3: A110.

20. Celli B., Calverley P.M.A., Anderson J.A., Ferguson G.T. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol / fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years (abstract). Eur. Respir. J. 2006; 28 (suppl. 50): 34s.

21. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.

22. Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912–919.

23. Nannini L., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2004; 3: Art No CD003794.pub2.

24. Sin D.D., Man S.F. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur. J. Pharmacol. 2006; 533: 28–35.

25. Adcock I.M., Maneechotesuwan K., Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J. Allergy Clin. Immunol. 2002; 110: S261– S268.

26. Roth M., Johnson P.R., Rudiger J.J. et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293–1299.

27. Edwards M.R., Johnson M.W., Johnston S.L. Combination therapy: synergistic suppression of virus induced chemokines in airway epithelial cells. Am. J. Respir. Cell. Mol. Biol. 2006; 34: 616–624.

28. Barnes N.C., Qiu Y.S., Pavord I.D. et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736–743.

29. Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol / fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007; 63: 938–943.

30. Stockley R.A., Chopra N., Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61: 122–128.

31. O'Donnell D.E., Sciurba F., Celli B. et al. Effect of fluticasone propionate / salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647–656.

32. Wouters E.F., Postma D.S., Fokkens B. et al. Withdrawal of fluticasone propionate from combined salmeterol / fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled trial. Thorax 2005; 60: 480–487.

33. Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.

34. James A.L., Palmer L.J., Kicic E. et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am. J. Respir. Crit. Care Med. 2005; 171: 109–114.

35. Lange P., Parner J., Vestbo J. et al. A 15 year follow up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998; 339: 1194–1200.

36. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 . The Lung Health Study. J. A. M. A. 1994; 272: 1497–1505.

37. Decramer M., Rutten#van Molken M., Dekhuijzen P.N. et al. Effects of Nacetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost Utility Study, BRONCUS): a randomised placebo controlled trial. Lancet 2005; 365: 1552–1560.

38. Johnson M., Rennard S. Alternative mechanisms for long acting beta(2) adrenergic agonists in COPD. Chest 2001; 120: 258–270.

39. Calverley P. Are inhaled corticosteroids systemic therapy for chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2004; 170: 721–722.

40. Donaldson G.C., Seemungal T.A.R., Bhowmik R., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.

41. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418–1422.

42. Wedzicha J.A., Calverley P. M. A., Seemungal T.A. et al. for the INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19–26.

43. Man S.F., Sin D.D. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 2005; 65: 579–591.

44. Appleton S., Poole P., Smith B. et al. Long-acting beta2 agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 3: CD001104.

45. Niewoehner D.E. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am. J. Med. 2006; 119 (10, suppl. 1): 38–45.

46. Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880–887.

47. Reardon J.Z., Lareau S.C., ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am. J. Med. 2006; 119 (10, suppl. 1): 32–37.

48. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 2002; 113: 59–65.

49. Sin D.D., Wu L., Anderson J.A. et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992–997.

50. Sin D.D., Tu J.V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 580–584.

51. Sin D.D., Man S.F. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur. Respir. J. 2003; 21: 260–266.

52. Soriano J.B., Vestbo J., Pride N.B. et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur. Respir. J. 2002; 20: 819–825.

53. Soriano J.B., Kiri V.A., Pride N.B., Vestbo J. Inhaled corticosteroids with / without long-acting beta agonists reduce the risk of rehospitalization and death in COPD patients. Am. J. Respir. Med. 2003; 2: 67–74.

54. Kiri V.A., Bettoncelli G., Testi R., Viegi G. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir. Med. 2005; 99: 1115–1124.

55. Mapel D.W., Hurley J.S., Roblin D. et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir. Med. 2006; 100: 595–609.

56. Rascati K.L., Stanford R.H., Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin. Ther. 2005; 27: 346–354.

57. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am. J. Respir. Crit. Care Med. 2003; 168: 49–53.

58. Fan V.S., Bryson C.L., Curtis J.R. et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time dependent analysis. Am. J. Respir. Crit. Care Med. 2003; 168: 1488–1494.

59. Kiri V.A., Pride N.B., Soriano J.B., Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am. J. Respir. Crit. Care Med. 2005; 172: 460–464.

60. Waterhouse J.C., Fishwick D., Anderson J.A., et al. What caused death in the ISOLDE study? Eur. Respir. J. 1999; 14 (suppl. 30): 387s.

61. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245–1257.

62. Altman D.G. Practical statistics for medical research. London: Chapman and Hall; 1991.

63. Pocock S.J. Clinical trials. London: John Wiley and Sons; 1984.

64. Shakespeare T.P., Gebski V.J., Veness M.J., Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves and risk benefit contours. Lancet 2001; 357: 1349–1353.

65. Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.

66. Flather M.D., Yusuf S., Kober L. et al. Long term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575–1581.

67. Wilt T.J., Bloomfield H.E., MacDonald R. et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. 2004; 164: 1427–1436.

68. Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A meta analysis. Thorax 2006; 61: 854–862.


Для цитирования:


Айсанов З.Р., Калманова Е.Н., Стулова О.Ю. Эффекты фиксированных комбинаций ингаляционных кортикостероидов и длительнодействующих β2-агонистов при хронической обструктивной болезни легких. Пульмонология. 2008;(6):101-108. https://doi.org/10.18093/0869-0189-2008-0-6-101-108

For citation:


Aisanov Z.R., Kalmanova E.N., Stulova O.Yu. Effects of fixed combinations of inhaled steroids and long-acting β2-agonists in chronic obstructive pulmonary disease. PULMONOLOGIYA. 2008;(6):101-108. (In Russ.) https://doi.org/10.18093/0869-0189-2008-0-6-101-108

Просмотров: 49


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)